AR035824A1 - Un compuesto de pirazol util como inhibidor de proteinquinasas, composiciones farmaceuticas que lo contienen, un metodo para inhibir la actividad de quinasas en una muestra biologica, una composicion para recubrir un dispositivo implantable y un dispositivo implantable recubierto con dicha composici - Google Patents
Un compuesto de pirazol util como inhibidor de proteinquinasas, composiciones farmaceuticas que lo contienen, un metodo para inhibir la actividad de quinasas en una muestra biologica, una composicion para recubrir un dispositivo implantable y un dispositivo implantable recubierto con dicha composiciInfo
- Publication number
- AR035824A1 AR035824A1 ARP020101360A ARP020101360A AR035824A1 AR 035824 A1 AR035824 A1 AR 035824A1 AR P020101360 A ARP020101360 A AR P020101360A AR P020101360 A ARP020101360 A AR P020101360A AR 035824 A1 AR035824 A1 AR 035824A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- optionally substituted
- nitrogen
- useful
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
Abstract
Un compuesto de pirazol útil como inhibidor de proteínquinasas que tiene la formula (1) o un derivado farmacéuticamente aceptable del mismo, donde: A y B se seleccionan independientemente entre N y CH; R1 y R2 se seleccionan independientemente cada uno entre halógeno, CN, NO2, N(R)2, OR, SR y (T)n-R5; R3 se selecciona entre un anillo carbocíclico o heterocíclico de 3 a 6 miembros que tenga 1 o 2 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre, fenilo, o un anillo de heteroarilo de 5 a 6 miembros que tenga de 1 a 3 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno y azufre, en donde dicho anillo fenilo o de heteroarilo está sustituido opcionalmente con un (T)n-Ar y de 1 a 2 R7; cada n se selecciona independientemente entre 0 y 1. T es una cadena de alquilideno C1-6, en donde una unidad de metileno de T se sustituye opcionalmente con CO, CO2, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO2, NRCONR, SO2, NRSO2, SO2NR, NRSO2NR, O, S o NR; cada R se selecciona independientemente entre hidrógeno o un grupo alifático C1-6 sustituido opcionalmente; o dos R en el mismo átomo de nitrógeno se pueden juntar con el nitrógeno para formar un anillo heterocíclico saturado o no saturado de 4 a 8 miembros que contenga de 1 a 3 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno y azufre; R4 es (T)n-R, (T)n-Ar o (T)n-Ar1; Ra se selecciona entre Rb, halógeno, NO2, ORb, SRb y N(Rb)2; Rb se selecciona entre hidrógeno y un grupo alifático C1-4 sustituido opcionalmente con oxo, OH, SH, NH2, halógeno, NO2 o CN; R5 es un C1-6 alifático o Ar sustituido opcionalmente; Ar es un anillo monocíclico saturado, parcialmente insaturado o de arilo de 5 o 6 miembros que tiene de 0 a 3 heteroátomos seleccionados independientemente entre nitrógeno, azufre y oxígeno, o un anillo bicíclico saturado, parcialmente insaturado o arilo de 8 a 10 miembros que tiene de 0 a 4 heteroátomos seleccionados independientemente entre nitrógeno, azufre y oxígeno, en donde Ar está sustituido opcionalmente con de 1 a 3 R7; Ar1 es un anillo de arilo de 6 miembros que tiene de 0 a 2 nitrógenos, en donde dicho anillo está sustituido con un grupo Z-R6 y sustituido opcionalmente con de 1 a 3 R7; Z es una cadena de alquilideno C1-6 en donde hasta 2 unidades de metileno no adyacentes de Z se reemplazan opcionalmente con CO, CO2, COCO, CONR, OCONR, NRNR, NRNRNCO, NRCO, NRCO2, NRCONR, SO, SO2, NRSO2, SO2NR, NRSO2NR, O, S o NR; siempre y cuando dicha unidad de metileno de Z reemplazada opcionalmente sea una unidad de metileno no adyacente a R6; R6 se selecciona entre Ar, R, halógeno, NO2, CN, OR, SR, N(R)2, NRC(O)R, NRC(O)N(R)2, NRCO2R, C(O)R, CO2R, OC(O)R, C(O)N(R)2, OC(O)N(R)2, SOR, SO2R, SO2N(R)2, NRSO2R, NRSO2N(R)2, C(O)C(O)R y C(O)CH2C(O)R; y cada R7 se selecciona independientemente entre R, halógeno, NO2, CN, OR, SR, N(R)2, NRC(O)R, NRC(O)N(R)2, NRCO2R, C(O)R, CO2R, C(O)N(R)2, OC(O)N(R)2, SOR, SO2R, SO2N(R)2, NRSO2R, NRSO2N(R)2, C(O)C(O)R y C(O)CH2C(O)R; o dos R7 en posiciones adyacentes de Ar1 se pueden juntar para formar un anillo de 5 a 7 miembros saturado, parcialmente insaturado o completamente insaturado, que contenga de 0 a 3 heteroátomos seleccionados entre O, S y N. La presente también proporcionar una composición farmacéutica que comprende un compuesto de la fórmula (1), un método para inhibir la actividad de quinasas en una muestra biológica, una composición para recubrir un dispositivo implantable y un dispositivo implantable recubierto con dicha composición. Los compuestos y composiciones farmacéuticas de la presente son útiles como inhibidores de quinasas N-terminales c-Jun (JNK) y quinasas de la familia Src, incluyendo Src y Lck. Por lo tanto, también son útiles en métodos para tratar o prevenir una amplia variedad de afecciones, como enfermedad cardíaca, afecciones de inmunodeficiencia, enfermedades inflamatorias, enfermedades alérgicas, enfermedades autoinmunes, afecciones oseodestructivas como osteoporosis, afecciones proliferativas, enfermedades infecciosas y enfermedades virales. Las composiciones también son útiles en métodos para prevenir la muerte celular e hiperplasia y por lo tanto se pueden usar para tratar o prevenir reperfusión/isquemia en embolia, ataques cardíacos e hipoxia de órganos. Las composiciones también son útiles en métodos para prevenir la agregación de plaquetas inducida por trombina. Las composiciones son especialmente útiles para afecciones como leucemia mielogénica crónica (CML), artritis reumatoide, asma, osteoartritis, isquemia, cáncer, enfermedades de hígado, incluyendo la isquemia hepática, enfermedades cardíacas como el infarto al miocardio y la insuficiencia cardíaca congestiva, afecciones inmunes patológicas que impliquen la activación de células T y trastornos neurodegenerativos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28362101P | 2001-04-13 | 2001-04-13 | |
US29297401P | 2001-05-23 | 2001-05-23 | |
US32944001P | 2001-10-15 | 2001-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035824A1 true AR035824A1 (es) | 2004-07-14 |
Family
ID=27403408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101360A AR035824A1 (es) | 2001-04-13 | 2002-04-12 | Un compuesto de pirazol util como inhibidor de proteinquinasas, composiciones farmaceuticas que lo contienen, un metodo para inhibir la actividad de quinasas en una muestra biologica, una composicion para recubrir un dispositivo implantable y un dispositivo implantable recubierto con dicha composici |
Country Status (12)
Country | Link |
---|---|
US (2) | US6642227B2 (es) |
EP (1) | EP1389206B1 (es) |
JP (1) | JP2004535381A (es) |
AR (1) | AR035824A1 (es) |
AT (1) | ATE339416T1 (es) |
AU (1) | AU2002338642A1 (es) |
CA (1) | CA2443487A1 (es) |
DE (1) | DE60214701T2 (es) |
ES (1) | ES2271322T3 (es) |
MX (1) | MXPA03009378A (es) |
TW (1) | TWI235752B (es) |
WO (1) | WO2002083667A2 (es) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912240A (en) * | 1997-04-10 | 1999-06-15 | Loria; Roger M. | 5-androstene 3β, 17α diol as an inhibitor of tumor growth |
BR0112969A (pt) | 2000-08-04 | 2004-06-22 | Dmi Biosciences Inc | Método de utilização de dicetopiperazinas e composições contendo-as |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
KR100876069B1 (ko) * | 2000-09-15 | 2008-12-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MXPA03005610A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
DE60214703T2 (de) * | 2001-06-01 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen |
JP4656838B2 (ja) * | 2002-02-06 | 2011-03-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Gsk−3の阻害剤として有用なヘテロアリール化合物 |
US20040009981A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
MXPA05001367A (es) * | 2002-08-02 | 2005-04-28 | Vertex Pharma | Composiciones de pirazol utiles como inhibidores de gsk-3. |
US7601718B2 (en) * | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
US7732403B2 (en) * | 2003-05-15 | 2010-06-08 | Dmi Biosciences, Inc. | Treatment of T-cell mediated diseases |
CA2548172A1 (en) * | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
JP2007531757A (ja) * | 2004-03-30 | 2007-11-08 | カイロン コーポレイション | 抗癌剤としての置換チオフェン誘導体 |
US20070293484A1 (en) * | 2004-05-20 | 2007-12-20 | Sugen, Inc. | Thiophene Heteroaryl Amines |
US20050267556A1 (en) * | 2004-05-28 | 2005-12-01 | Allan Shuros | Drug eluting implants to prevent cardiac apoptosis |
ES2396135T3 (es) * | 2004-06-10 | 2013-02-19 | Irm Llc | Compuestos y composiciones como inhibidores de proteínas cinasas |
US20060018123A1 (en) * | 2004-07-02 | 2006-01-26 | Rose Eric P | Curing light having a reflector |
RU2007114080A (ru) * | 2004-10-13 | 2008-11-27 | Вайет (Us) | N-бензилсульфонил-замещенные аналоги анилинопиримидина |
EP1809636A1 (en) | 2004-10-19 | 2007-07-25 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
KR20070086188A (ko) * | 2004-11-17 | 2007-08-27 | 미카나 테라퓨틱스, 인크. | 키나제 억제제 |
US20110144128A1 (en) * | 2005-01-10 | 2011-06-16 | Exelixis, Inc. | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands |
US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
US20080194561A1 (en) * | 2005-07-26 | 2008-08-14 | Jerry Leroy Adams | Compounds |
AU2006279376B2 (en) * | 2005-08-18 | 2011-04-14 | Vertex Pharmaceuticals Incoporated | Pyrazine kinase inhibitors |
BRPI0616630B8 (pt) * | 2005-09-30 | 2021-05-25 | Miikana Therapeutics Inc | compostos de pirazol substituídos |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
PT1951684T (pt) * | 2005-11-01 | 2016-10-13 | Targegen Inc | Inibidores de cinases de tipo biaril-meta-pirimidina |
EP1951715B1 (en) * | 2005-11-03 | 2013-09-04 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CA2628474A1 (en) * | 2005-11-03 | 2007-05-10 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
US20080085293A1 (en) * | 2006-08-22 | 2008-04-10 | Jenchen Yang | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor |
CA2663545A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
ATE457311T1 (de) * | 2006-11-02 | 2010-02-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine |
DE602007007985D1 (de) * | 2006-12-19 | 2010-09-02 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyrimidine |
ES2435997T3 (es) * | 2007-03-09 | 2013-12-26 | Vertex Pharmaceuticals, Inc. | Aminopirimidinas útiles como inhibidores de las proteínas cinasas |
CA2679701A1 (en) | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
MX2009009591A (es) * | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
WO2008128009A2 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CA2688584A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2008137621A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
JP5389785B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
EP2164842A2 (en) * | 2007-05-24 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
JP2010529193A (ja) * | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
AU2008282156B2 (en) * | 2007-07-31 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
WO2009094224A1 (en) | 2008-01-25 | 2009-07-30 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
WO2009103032A1 (en) | 2008-02-15 | 2009-08-20 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
EP2259677A4 (en) * | 2008-02-29 | 2011-11-02 | Alseres Pharmaceuticals Inc | SYSTEMIC PURINARY ADMINISTRATION FOR MODULATING THE AXONAL GROWTH OF THE CENTRAL NERVOUS SYSTEM |
US8217047B2 (en) | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
US8680113B2 (en) * | 2008-07-01 | 2014-03-25 | Ptc Therapeutics, Inc. | BMI-1 protein expression modulators |
RU2011112802A (ru) * | 2008-09-03 | 2012-10-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Сокристаллы и содержащие их фармацевтические композиции |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
US9090601B2 (en) * | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
CN102395585A (zh) * | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
SG173584A1 (en) * | 2009-02-06 | 2011-09-29 | Elan Pharm Inc | Inhibitors of jun n-terminal kinase |
WO2011034962A2 (en) * | 2009-09-16 | 2011-03-24 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
KR101682092B1 (ko) * | 2009-11-12 | 2016-12-05 | 삼성디스플레이 주식회사 | 박막 트랜지스터 표시판 및 이를 포함하는 액정 표시 장치 |
US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
EP2603216A4 (en) | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
CN103153300A (zh) | 2010-08-11 | 2013-06-12 | 米伦纽姆医药公司 | 杂芳基化合物和其用途 |
US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
CA2810844C (en) | 2010-09-07 | 2017-03-21 | Dmi Acquisition Corp. | Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions |
SG189396A1 (en) | 2010-10-13 | 2013-05-31 | Millennium Pharm Inc | Heteroaryls and uses thereof |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
CA2815330A1 (en) * | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
PL2766029T3 (pl) | 2011-10-10 | 2020-08-24 | Ampio Pharmaceuticals, Inc. | Leczenie choroby zwyrodnieniowej stawów |
WO2013055749A1 (en) | 2011-10-10 | 2013-04-18 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
JP6231484B2 (ja) | 2011-10-28 | 2017-11-15 | アンピオ ファーマシューティカルズ,インコーポレイテッド | 鼻炎の処置 |
AU2013216935C1 (en) | 2012-02-08 | 2017-12-14 | John Emmerson Campbell | Heteroaryl compounds and methods of use thereof |
PT2841428T (pt) | 2012-04-24 | 2018-11-29 | Vertex Pharma | Inibidores de adn-pk |
EP3985003B1 (en) | 2013-03-12 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
CN105101965B (zh) | 2013-03-15 | 2021-03-09 | 安皮奥制药股份有限公司 | 用于干细胞活动化、归巢、扩增和分化的组合物及其使用方法 |
CN105814036B (zh) | 2013-10-17 | 2018-10-26 | 沃泰克斯药物股份有限公司 | 作为dna-pk抑制剂的共晶 |
MY176401A (en) | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
RU2736513C2 (ru) | 2014-08-18 | 2020-11-17 | Ампио Фармасьютикалз, Инк. | Лечение патологических состояний суставов |
EP3310375A4 (en) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES |
EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
MA45857A (fr) | 2016-07-29 | 2021-05-19 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
JP6654116B2 (ja) | 2016-08-12 | 2020-02-26 | 浜松ホトニクス株式会社 | リニアイメージセンサおよびその製造方法 |
KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
EP3938045A1 (en) | 2019-03-14 | 2022-01-19 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
WO2020263989A1 (en) * | 2019-06-24 | 2020-12-30 | University Of Iowa Research Foundation | Jnk inhibitors as anticancer agents |
US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
TW202332448A (zh) * | 2021-11-15 | 2023-08-16 | 美商艾瑞斯卡公司 | 噻吩ulk1/2抑制劑及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4940712A (en) | 1989-05-26 | 1990-07-10 | Pfizer Inc. | Derivatives of hydroxyprimidines as leukotriene synthesis inhibitors |
IL112290A (en) | 1994-01-12 | 1999-01-26 | Novartis Ag | Transformed aryl and the troiryl pyrimidines and herbicides containing them |
AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
CA2230896A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
WO1998028282A2 (en) | 1996-12-23 | 1998-07-02 | Du Pont Pharmaceuticals Company | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS |
JP2002502379A (ja) * | 1997-05-22 | 2002-01-22 | ジー.ディー.サール アンド カンパニー | p38キナーゼインヒビターとしての3(5)−ヘテロアリール置換ピラゾール |
AU732406B2 (en) * | 1997-10-03 | 2001-04-26 | Merck Frosst Canada & Co. | Aryl thiophene derivatives as PDE IV inhibitors |
MXPA02001565A (es) * | 1999-08-13 | 2005-07-14 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas. |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
-
2002
- 2002-04-10 AT AT02762067T patent/ATE339416T1/de not_active IP Right Cessation
- 2002-04-10 JP JP2002581422A patent/JP2004535381A/ja not_active Withdrawn
- 2002-04-10 ES ES02762067T patent/ES2271322T3/es not_active Expired - Lifetime
- 2002-04-10 EP EP02762067A patent/EP1389206B1/en not_active Expired - Lifetime
- 2002-04-10 MX MXPA03009378A patent/MXPA03009378A/es unknown
- 2002-04-10 WO PCT/US2002/011570 patent/WO2002083667A2/en active IP Right Grant
- 2002-04-10 AU AU2002338642A patent/AU2002338642A1/en not_active Abandoned
- 2002-04-10 US US10/121,035 patent/US6642227B2/en not_active Expired - Fee Related
- 2002-04-10 DE DE60214701T patent/DE60214701T2/de not_active Expired - Lifetime
- 2002-04-10 CA CA002443487A patent/CA2443487A1/en not_active Abandoned
- 2002-04-12 AR ARP020101360A patent/AR035824A1/es unknown
- 2002-04-12 TW TW091107461A patent/TWI235752B/zh not_active IP Right Cessation
-
2003
- 2003-05-14 US US10/437,666 patent/US7084159B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2002338642A1 (en) | 2002-10-28 |
US20030096816A1 (en) | 2003-05-22 |
ATE339416T1 (de) | 2006-10-15 |
TWI235752B (en) | 2005-07-11 |
US20040023963A1 (en) | 2004-02-05 |
US6642227B2 (en) | 2003-11-04 |
US7084159B2 (en) | 2006-08-01 |
EP1389206A2 (en) | 2004-02-18 |
DE60214701D1 (de) | 2006-10-26 |
JP2004535381A (ja) | 2004-11-25 |
WO2002083667A3 (en) | 2003-01-03 |
ES2271322T3 (es) | 2007-04-16 |
WO2002083667A2 (en) | 2002-10-24 |
EP1389206B1 (en) | 2006-09-13 |
MXPA03009378A (es) | 2004-01-29 |
DE60214701T2 (de) | 2007-09-13 |
CA2443487A1 (en) | 2002-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035824A1 (es) | Un compuesto de pirazol util como inhibidor de proteinquinasas, composiciones farmaceuticas que lo contienen, un metodo para inhibir la actividad de quinasas en una muestra biologica, una composicion para recubrir un dispositivo implantable y un dispositivo implantable recubierto con dicha composici | |
RU2345996C1 (ru) | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения | |
RU2007146769A (ru) | Бициклические производные и их применение в качестве модуляторов ионых каналов | |
EA200401378A1 (ru) | N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора | |
AR057769A1 (es) | Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas | |
RU2007123360A (ru) | Пирролопиразины и пиразолопиразины, полезные в качестве ингибиторов протеинкиназ | |
AR049333A1 (es) | Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas. | |
AR046758A1 (es) | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
EA200800924A1 (ru) | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера | |
AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
CO4820390A1 (es) | Quinazolinas substituidas y bioisoesteres como inhibidores de la tirosina cinasa c-erb b- 2 | |
PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
AR038481A1 (es) | Derivados de dihidrobenzodiazepin-2-ona iii para el tratamiento de desordenes neurologicos | |
AR073920A1 (es) | Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion. | |
AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
PE20040893A1 (es) | DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA | |
EA200400113A1 (ru) | Ингибиторы вирусной полимеразы | |
CR8595A (es) | Inhibidor del dipeptidil-peptidasa | |
AR057034A1 (es) | Metodos para purificar tigeciclina | |
WO2009006404A3 (en) | Heterocyclic compounds useful as raf kinase inhibitors | |
ES2518316T3 (es) | Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia | |
AR115871A1 (es) | MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |